|
US4256108A
(en)
|
1977-04-07 |
1981-03-17 |
Alza Corporation |
Microporous-semipermeable laminated osmotic system
|
|
US4160452A
(en)
|
1977-04-07 |
1979-07-10 |
Alza Corporation |
Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
|
|
US4265874A
(en)
|
1980-04-25 |
1981-05-05 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
|
US5007790A
(en)
|
1989-04-11 |
1991-04-16 |
Depomed Systems, Inc. |
Sustained-release oral drug dosage form
|
|
US5169645A
(en)
|
1989-10-31 |
1992-12-08 |
Duquesne University Of The Holy Ghost |
Directly compressible granules having improved flow properties
|
|
US5582837A
(en)
|
1992-03-25 |
1996-12-10 |
Depomed, Inc. |
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
|
|
ES2124303T3
(es)
|
1992-03-25 |
1999-02-01 |
Depomed Inc |
Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
|
|
AU3290397A
(en)
|
1996-06-10 |
1998-01-07 |
Depomed, Inc. |
Gastric-retentive oral controlled drug delivery system with enhanced retention properties
|
|
US5972389A
(en)
|
1996-09-19 |
1999-10-26 |
Depomed, Inc. |
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
|
|
AU5923998A
(en)
|
1997-01-31 |
1998-08-25 |
Avid Therapeutics Inc. |
2-benzoylamino-3-phenylpropenamide derivatives and methods of using the same
|
|
WO1998055107A1
(en)
|
1997-06-06 |
1998-12-10 |
Depomed, Inc. |
Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
|
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
|
US6323219B1
(en)
|
1998-04-02 |
2001-11-27 |
Ortho-Mcneil Pharmaceutical, Inc. |
Methods for treating immunomediated inflammatory disorders
|
|
HK1050135A1
(zh)
|
1999-11-02 |
2003-06-13 |
Depomed, Inc. |
用於促进将药物给予胃的饭後模式药理学诱导
|
|
WO2001037820A2
(en)
*
|
1999-11-24 |
2001-05-31 |
Sugen, Inc. |
Ionizable indolinone derivatives and their use as ptk ligands
|
|
DE60123384T2
(de)
|
2000-02-04 |
2007-08-02 |
DepoMed, Inc., Menlo Park |
Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
|
|
US6488962B1
(en)
|
2000-06-20 |
2002-12-03 |
Depomed, Inc. |
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
|
|
US6451808B1
(en)
|
2000-10-17 |
2002-09-17 |
Depomed, Inc. |
Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
|
|
MXPA03011096A
(es)
|
2001-05-29 |
2004-12-06 |
Depomed Dev Ltd |
Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
|
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
|
CA2409552A1
(en)
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
|
JP2005508358A
(ja)
|
2001-10-25 |
2005-03-31 |
デポメド・インコーポレイテッド |
胃滞留型ロサルタン投与量を用いる治療方法
|
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
|
US20080261913A1
(en)
|
2006-12-28 |
2008-10-23 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of liver disorders
|
|
US8816074B2
(en)
|
2009-11-16 |
2014-08-26 |
University of Georgia Foundation, Inc. |
2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
|
|
SG184324A1
(en)
|
2010-03-31 |
2012-11-29 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
US8921381B2
(en)
|
2010-10-04 |
2014-12-30 |
Baruch S. Blumberg Institute |
Inhibitors of secretion of hepatitis B virus antigens
|
|
EA024762B9
(ru)
|
2011-06-30 |
2017-04-28 |
Эрроухэд Рисерч Корпорейшн |
Композиции и способы ингибирования экспрессии генов вируса гепатита в
|
|
JP5977347B2
(ja)
|
2011-07-01 |
2016-08-24 |
バルーク エス．ブルームバーグ インスティテュート |
Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体
|
|
BR112014015197A8
(pt)
|
2011-12-21 |
2017-06-13 |
Novira Therapeutics Inc |
agentes antivirais de hepatite b
|
|
BR112014021498A2
(pt)
|
2012-02-29 |
2017-07-18 |
Institute For Hepatitis And Virus Res |
composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
|
|
US20130267517A1
(en)
|
2012-03-31 |
2013-10-10 |
Hoffmann-La Roche Inc. |
Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
ES2575398T3
(es)
|
2012-03-31 |
2016-06-28 |
F. Hoffmann-La Roche Ag |
4-Metil-dihidropirimidinas novedosas para el tratamiento y la profilaxis de la infección por el virus de la hepatitis B
|
|
KR102271574B1
(ko)
|
2012-08-28 |
2021-07-01 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
|
|
EA026957B1
(ru)
|
2012-08-28 |
2017-06-30 |
Янссен Сайенсиз Айрлэнд Юси |
Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
|
|
WO2014089296A2
(en)
|
2012-12-06 |
2014-06-12 |
Institute For Hepatitis And Virus Research |
Functionalized benzamide derivatives as antiviral agents against hbv infection
|
|
BR112015015584A2
(pt)
|
2012-12-27 |
2017-12-12 |
Baruch S Blumberg Inst |
novos agentes antivirais contra infecção por hbv
|
|
WO2014131847A1
(en)
|
2013-02-28 |
2014-09-04 |
Janssen R&D Ireland |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
|
US9187454B2
(en)
*
|
2013-03-13 |
2015-11-17 |
Boston Biomedical, Inc. |
Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
|
|
MX353412B
(es)
|
2013-04-03 |
2018-01-10 |
Janssen Sciences Ireland Uc |
Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
|
|
DK2997019T3
(en)
|
2013-05-17 |
2018-12-03 |
Janssen Sciences Ireland Uc |
SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
|
|
TWI733288B
(zh)
|
2013-05-17 |
2021-07-11 |
愛爾蘭商健生科學愛爾蘭無限公司 |
胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
|
|
WO2015005901A1
(en)
|
2013-07-09 |
2015-01-15 |
Bristol-Myers Squibb Company |
Combinations of hepatitis c virus inhibitors
|
|
HRP20180791T1
(hr)
|
2013-07-25 |
2018-09-07 |
Janssen Sciences Ireland Uc |
Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
|
|
CA2923712C
(en)
|
2013-10-23 |
2021-11-02 |
Janssen Sciences Ireland Uc |
Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
WO2015073774A1
(en)
|
2013-11-14 |
2015-05-21 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis b infections
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
EA201691261A1
(ru)
|
2014-01-30 |
2016-11-30 |
Ф. Хоффманн-Ля Рош Аг |
Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
|
|
TW201620893A
(zh)
|
2014-02-06 |
2016-06-16 |
健生科學愛爾蘭無限公司 |
磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途
|
|
AU2015226206B2
(en)
|
2014-03-07 |
2017-03-16 |
F. Hoffmann-La Roche Ag |
Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
|
|
ES2748029T3
(es)
|
2014-03-13 |
2020-03-12 |
Univ Indiana Res & Tech Corp |
Moduladores alostéricos de proteína núcleo de hepatitis B
|
|
KR20160148715A
(ko)
|
2014-05-13 |
2016-12-26 |
에프. 호프만-라 로슈 아게 |
B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 다이하이드로퀴놀리진온
|
|
CN106459061B
(zh)
|
2014-05-30 |
2020-01-21 |
齐鲁制药有限公司 |
作为hbv抑制剂的二氢嘧啶并环衍生物
|
|
CN105367550A
(zh)
*
|
2014-08-11 |
2016-03-02 |
江苏柯菲平医药股份有限公司 |
四氢环戊二烯并[c]吡咯类衍生物、其制备方法及其在医药上的应用
|
|
BR112017002970B1
(pt)
|
2014-08-14 |
2023-04-11 |
F. Hoffmann-La Roche Ag |
Novas piridazonas e triazinonas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
|
|
US9637485B2
(en)
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
|
CN107406378A
(zh)
|
2014-12-02 |
2017-11-28 |
诺维拉治疗公司 |
用于hbv治疗的硫化烷基化合物和吡啶类反式磺酰胺化合物
|
|
CN107108610B
(zh)
|
2014-12-30 |
2019-06-04 |
豪夫迈·罗氏有限公司 |
用于治疗和预防肝炎b病毒感染的新的四氢吡啶并嘧啶和四氢吡啶并吡啶化合物
|
|
HK1244281B
(zh)
|
2015-02-11 |
2020-02-07 |
F. Hoffmann-La Roche Ag |
治疗和预防乙型肝炎病毒感染的2-氧代-6，7-二氢苯并[a]喹嗪-3-甲酸衍生物
|
|
WO2016177655A1
(en)
|
2015-05-04 |
2016-11-10 |
F. Hoffmann-La Roche Ag |
Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
|
|
WO2016183266A1
(en)
|
2015-05-13 |
2016-11-17 |
Enanta Pharmaceuticals, Inc. |
Ehpatitis b antiviral agents
|
|
US10875876B2
(en)
*
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
US10179131B2
(en)
|
2015-07-13 |
2019-01-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
CN107849037B
(zh)
|
2015-07-21 |
2020-04-17 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的三环4-吡啶酮-3-甲酸衍生物
|
|
WO2017015451A1
(en)
|
2015-07-22 |
2017-01-26 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
WO2017016960A1
(en)
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
|
|
WO2017016921A1
(en)
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
New crystalline forms of (6s)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
|
JP6506880B2
(ja)
|
2015-07-27 |
2019-04-24 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウィルス感染症の治療および予防のための新規な四環式４−オキソ−ピリジン−３−カルボン酸誘導体
|
|
WO2017017043A1
(en)
|
2015-07-28 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
|
|
TWI721016B
(zh)
|
2015-09-15 |
2021-03-11 |
美商艾森伯利生物科學公司 |
B型肝炎核心蛋白質調節劑
|
|
WO2017064156A1
(en)
|
2015-10-16 |
2017-04-20 |
F. Hoffmann-La Roche Ag |
Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
WO2017102648A1
(en)
|
2015-12-15 |
2017-06-22 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and a nucleos(t)ide analogue
|
|
MA44075A
(fr)
|
2015-12-17 |
2021-05-19 |
Incyte Corp |
Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
|
|
WO2017108630A1
(en)
|
2015-12-21 |
2017-06-29 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
|
|
WO2017114812A1
(en)
|
2015-12-29 |
2017-07-06 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and an interferon
|
|
US20200270265A1
(en)
|
2016-02-19 |
2020-08-27 |
Novartis Ag |
Tetracyclic pyridone compounds as antivirals
|
|
CA3020585A1
(en)
|
2016-04-11 |
2017-10-19 |
Arbutus Biopharma Corporation |
Targeted nucleic acid conjugate compositions
|
|
JP2019530732A
(ja)
|
2016-08-03 |
2019-10-24 |
アライジング・インターナショナル・インコーポレイテッドＡｒｉｓｉｎｇ Ｉｎｔｅｒｎａｔｉｏｎａｌ， Ｉｎｃ． |
免疫モジュレータとして有用な対称または半対称化合物
|
|
JOP20190024A1
(ar)
*
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
WO2018044783A1
(en)
|
2016-08-29 |
2018-03-08 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
US10144706B2
(en)
|
2016-09-01 |
2018-12-04 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
WO2018045142A1
(en)
|
2016-09-02 |
2018-03-08 |
Polaris Pharmaceuticals, Inc. |
Immune checkpoint inhibitors, compositions and methods thereof
|
|
SG11201902944TA
(en)
|
2016-11-07 |
2019-05-30 |
Arbutus Biopharma Corp |
Substituted pyridinone-containing tricyclic compounds, and methods using same
|
|
EP3558970B1
(en)
|
2016-12-20 |
2021-09-01 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
WO2018119221A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Pyridine derivatives as immunomodulators
|
|
ES2874756T3
(es)
|
2016-12-22 |
2021-11-05 |
Incyte Corp |
Derivados de triazolo[1,5-A]piridina como inmunomoduladores
|
|
JP7101678B2
(ja)
|
2016-12-22 |
2022-07-15 |
インサイト・コーポレイション |
免疫調節剤としての複素環式化合物
|
|
US20180179202A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
EP3564237A4
(en)
|
2016-12-29 |
2020-06-10 |
Shenzhen Chipscreen Biosciences Co., Ltd. |
UREA COMPOUND AND PRODUCTION METHOD AND USE THEREOF
|
|
WO2018133845A1
(zh)
*
|
2017-01-23 |
2018-07-26 |
上海长森药业有限公司 |
硫脲类、脲类化合物及其用途
|
|
CN109678796B
(zh)
|
2017-10-19 |
2023-01-10 |
上海长森药业有限公司 |
Pd-1/pd-l1小分子抑制剂及其制备方法和用途
|
|
US11629135B2
(en)
|
2017-11-06 |
2023-04-18 |
Jubilant Prodell Llc |
Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
|